General The prevalence of<unk>  in the general population is approximately 1-3%.<unk>  cases usually occur between the ages of 12.4 and 24.7, but prevalence rates increase until the age of 40.<unk>  is the most common<unk><unk>  in adults. The limited amount of research that has been done on<unk>  shows that rates of<unk>  are fairly comparable among men and women. The lifetime prevalence of<unk>  has been observed in studies to be 2.0 percent for men and 3.5 percent for women, higher than that of the commonly recognized<unk><unk> s anorexia nervosa and bulimia nervosa. However another systematic literature review found the prevalence average to be about 2.3% in women and about 0.3% in men. Lifetime prevalence rates for<unk>  in women can range anywhere from 1.5 to 6 times higher than in men. One literature review found that point prevalence rates for<unk>  vary from 0.1 percent to 24.1 percent depending on the sample. This same review also found that the 12-month prevalence rates vary between 0.1 percent to 8.8 percent. Recent studies found that<unk><unk> s which included anorexia nervosa, bulimia nervosa and<unk>  are common among sexual and gender minority populations, including gay, lesbian, bisexual and transgender people. This could be due to the minority stress and discrimination this population experiences. Due to limited and inconsistent information and research on ethnic and racial differences, prevalence rates are hard to determine for<unk> . Rates of<unk>  have been found to be similar among black women, white women, and white men, while some studies have shown that<unk>  is more common among black women than among white women. However, majority of the research done around<unk>  is focused on White women. One literature review found information citing no difference between<unk>  prevalence among Hispanic, African American, and White women while other information found that<unk>  prevalence was highest among Hispanics followed by Black individuals and finally White people. Worldwide Prevalences<unk><unk> s have usually been considered something that was specific to Western countries. However, the prevalence of<unk><unk> s is increasing in other non-Western countries. Though the research on<unk> s tends to be concentrated in North America, the<unk>  occurs across cultures. In the USA,<unk>  is present in 0.8% of male adults and 1.6% of female adults in a given year. The prevalence of<unk>  is lower in Nordic countries compared to Europe in a study that included Finland, Sweden, Norway, and Iceland. The point prevalence ranged from 0.4 to 1.5 percent and the lifetime prevalence ranged from 0.7 to 5.8 percent for<unk>  in women. In a study that included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela, the point prevalence for<unk>  was 3.53 percent. Therefore, this particular study found that the prevalence for<unk>  is higher in these Latin American countries compared to Western countries. The prevalence of<unk>  in Europe ranges from <1 to 4 percent. Co-morbidities<unk>  is co-morbid with diabetes, hypertension, previous stroke, and heart disease in some individuals. In people who have obsessive-compulsive<unk>  or bipolar I or II<unk> s,<unk>  lifetime prevalence was found to be higher. Additionally, 30 to 40 percent of individuals seeking treatment for weight-loss can be diagnosed with<unk> . Underreporting in men<unk><unk> s are oftentimes underreported in men. Underreporting could be a result of measurement bias due to how<unk><unk> s are defined. The current definition for<unk><unk> s focuses on thinness. However,<unk><unk> s in men tend to center on muscularity and would therefore warrant a need for a different measurement definition. Further research should focus on including more men in samples since previous research has focused primarily on women.
Binge eating disorder
Bulimia nervosa
Night eating syndrome
Metabolically healthy obesity
Anorexia nervosa
Orthorexia nervosa
Diabulimia
Nocturnal sleep-related eating disorder